Sugi Predict

Sugi Predict / Compounds / SCHEMBL4550680

SCHEMBL4550680

SCHEMBL4550680

Nc1nc2c(ncn2C[C@]2(CO)C[C@H]2CO)c(=O)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 2/20 0.55
▸ BLM P54132 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ VCP P55072 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ PNP P00491 7/20 0.54
▸ USP2 O75604 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ EDNRA P25101 1/20 0.54
▸ HTR2A P28223 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ HBB P68871 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ ADORA3 P0DMS8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17591528 1.00 TK1 (0.55) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL7453741 1.00 TK1 (0.55) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL9260998 1.00 TK1 (0.55) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL4550681 1.00 TK1 (0.55) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL8053194 0.99 TK1 (0.54) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL8067159 0.99 TK1 (0.54) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL9836916 0.89 TK1 (0.57) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL13058159 0.83 HPRT1 (0.50) ALDH1A1LMNAPNPADORA3HPRT1
SCHEMBL6943828 0.82 ADORA3 (0.37) TK1BLMMEN1ALDH1A1LMNA
SCHEMBL7452553 0.80 HDAC6 (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122076158-A Ultra-high-purity supercritical carbon dioxide purification system — 2026-05-26 — — CN claimed
US-20260069720-A1 EYE DROP COMPOSITION ARATANA THERAPEUTICS INC (US) 2026-03-12 — — US claimed
US-12465658-B2 Eye drop composition Aratana Therapeutics, Inc. (US) 2025-11-11 — — US claimed
CN-118324764-A Synthesis method of nucleoside Eprociclovir and analogues thereof 南阳理工学院 2024-07-12 — — CN claimed
US-20240148909-A1 EYE DROP COMPOSITION Aratana Therapeutics, Inc. 2024-05-09 — — US claimed
US-11904024-B2 Eye drop composition Aratana Therapeutics, Inc. (US) 2024-02-20 — — US claimed
US-20210205478-A1 EYE DROP COMPOSITION Aratana Therapeutics, Inc. 2021-07-08 — — US claimed
US-10967074-B2 Eye drop composition Aratana Therapeutics, Inc. (US) 2021-04-06 — — US claimed
US-20160346287-A1 METHOD OF TREATING VIRAL INFECTIONS EPIPHANY BIOSCIENCES, INC. 2016-12-01 — — US claimed
EP-2804582-B1 EYE DROP COMPOSITION ARATANA THERAPEUTICS NV (BE) 2016-03-30 — — EP claimed
US-20150352118-A1 EYE DROP COMPOSITION ARATANA THERAPEUTICS NV (BE) 2015-12-10 — — US claimed
US-9107943-B2 Eye drop composition ARATANA THERAPEUTICS NV (BE) 2015-08-18 — — US claimed
US-20150098904-A1 EYE DROP COMPOSITION ARATANA THERAPEUTICS NV (BE) 2015-04-09 — — US claimed
US-20150050241-A1 METHOD OF TREATING VIRAL INFECTIONS EPIPHANY BIOSCIENCES, INC. 2015-02-19 — — US claimed
EP-2804582-A1 EYE DROP COMPOSITION Aratana Therapeutics NV (BE) 2014-11-26 — — EP claimed
WO-2013107515-A1 EYE DROP COMPOSITION OKAPI SCIENCES NV (BE) 2013-07-25 — — WO claimed
EP-0890574-B1 Method for purifying nucleic acid derivatives AJINOMOTO KK (JP) 2003-03-12 — — EP claimed
US-6331528-B1 EXPRESSING THYMIDINE KINASE GENE IN CELL AND ADMINISTERING9-(1*,2*-BIS(HYDROXYMETHYL)CYCLOPROPAN-1*-YL)METH YLGUANINE AJINOMOTO CO., INC. (JP) 2001-12-18 — — US claimed
CN-122076158-A Ultra-high-purity supercritical carbon dioxide purification system — 2026-05-26 — — CN disclosed
US-5342840-A Viricides AJINOMOTO CO., INC. (JP) 1994-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346287-A1 METHOD OF TREATING VIRAL INFECTIONS IFNG, BCL9, GDA TK1 337/4885BLM 37/4885MEN1 74/4885
US-20150352118-A1 EYE DROP COMPOSITION P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885
US-20260069720-A1 EYE DROP COMPOSITION PDE6D, PDE6C, PURB TK1 3320/4885BLM 3995/4885MEN1 3139/4885
US-12465658-B2 Eye drop composition P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885
US-20150050241-A1 METHOD OF TREATING VIRAL INFECTIONS IFNG, BCL9, GDA TK1 337/4885BLM 37/4885MEN1 74/4885
US-20150098904-A1 EYE DROP COMPOSITION P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885
US-20210205478-A1 EYE DROP COMPOSITION P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885
US-11904024-B2 Eye drop composition P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885
US-10967074-B2 Eye drop composition P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885
US-20240148909-A1 EYE DROP COMPOSITION P2RY1, P2RY6, PDE6C TK1 2308/4885BLM 3836/4885MEN1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.